Quotient is focusing on Autoimmune and Inflammatory conditions where we see significant unmet need.
Inflammatory/autoimmune treatment products are particularly attractive revenue producers, as they need to be taken on a continuing basis, which accounts for the oversized market potential. It is estimated that 8-9% of the population, or over 25 million people, suffer from inflammatory/autoimmune diseases just in the US.
As Quotient develops these initial product offerings, it will explore other potential applications, including but not limited to:
Autoimmune and Inflammatory Diseases
This category includes rheumatoid and psoriatic arthritis, Crohn's disease, and many others, affecting severely over 10 million people in the United States. Several biologics have become mainstay treatments for some of these conditions with sales totaling some over $40 billion per year worldwide. Several products are among the largest revenue producers in history. These biologics can be associated with serious side effects and rarely lead to symptom elimination. One common and severe side effect is a diminished ability to fight infection. These biologics generally bind to only one target molecule, which can limit their effectiveness in patient populations.
Quotient believes its products may be able to demonstrate performance superior to that of existing therapies and it's human antibody is immune-boosting and fundamentally safe, in sharp contrast to the immune-suppressive behavior of these biologics. We expect a true product distinction and advantage for Quotient against these competing synthesized monoclonal products, offering an exceptional business opportunity
Inflammatory/autoimmune treatment products are particularly attractive revenue producers, as they need to be taken on a continuing basis, which accounts for the oversized market potential. It is estimated that 8-9% of the population, or over 25 million people, suffer from inflammatory/autoimmune diseases just in the US.
As Quotient develops these initial product offerings, it will explore other potential applications, including but not limited to:
Autoimmune and Inflammatory Diseases
This category includes rheumatoid and psoriatic arthritis, Crohn's disease, and many others, affecting severely over 10 million people in the United States. Several biologics have become mainstay treatments for some of these conditions with sales totaling some over $40 billion per year worldwide. Several products are among the largest revenue producers in history. These biologics can be associated with serious side effects and rarely lead to symptom elimination. One common and severe side effect is a diminished ability to fight infection. These biologics generally bind to only one target molecule, which can limit their effectiveness in patient populations.
Quotient believes its products may be able to demonstrate performance superior to that of existing therapies and it's human antibody is immune-boosting and fundamentally safe, in sharp contrast to the immune-suppressive behavior of these biologics. We expect a true product distinction and advantage for Quotient against these competing synthesized monoclonal products, offering an exceptional business opportunity